Stocks · News reference
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted the Marketing Authorisation Application for Ultragenyx's investigational gene therapy, rebisufligene etisparvovec, for the treatment of MPS IIIA.
Ultragenyx announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) accepted its Marketing Authorisation Application for rebisufligene etisparvovec (UX111), an investigational gene therapy for MPS IIIA (Sanfilippo syndrome Type A). The company has also coordinated with NICE to align the evaluation timeline with the regulatory review process. The therapy received FDA approval in September 2026 and is also under review by the European Medicines Agency.
Zeo Energy Corp. has implemented a leadership realignment, including several executive promotions and role transitions, to support its residential solar business and commercial expansion.
A Snowflake insider has sold company shares valued at approximately $3.06 million, according to a recent filing with the U.S. Securities and Exchange Commission.
The US Food and Drug Administration has granted Orphan Drug Designation to HUTCHMED's sovleplenib for the treatment of autoimmune hemolytic anemia.